CG Oncology, Inc. (CGON) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $66.23: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum.
CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene, an oncolytic immunotherapy targeting bladder cancer. No product revenues to date; pursuing FDA BLA submission based on Phase 3 BOND-003 data.
Sell if holding. Engine safety override at $66.23: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductcretostimogene10-K Item 1A: 'We currently depend entirely on the success of cretostimogene, which is our only product candidate.'
- HIGHSupplierBiovire and third parties for cretostimogene manufacture10-K Item 1A: 'We rely on Biovire and third parties for the manufacture and shipping of cretostimogene for clinical development'
Material Events(8-K, last 90d)
- 2026-04-13Item 5.02MEDIUMJim DeTore appointed CFO on April 13, 2026. DeTore had served as Interim Principal Financial and Accounting Officer since November 2025; converts interim to permanent. No disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $66.23: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $61.65. Score 5.0/10, moderate confidence.
Take-profit target: $76.44 (+15.3% upside). Prior stop was $61.65. Stop-loss: $61.65.
Concentration risk — Product: cretostimogene; Concentration risk — Supplier: Biovire and third parties for cretostimogene manufacture; Quality below floor (1.7 < 4.0).
CG Oncology, Inc. trades at a P/E of N/A (forward -32.9). TrendMatrix value score: 7.5/10. Verdict: Sell.
21 analysts cover CGON with a consensus score of 4.2/5. Average price target: $88.
What does CG Oncology, Inc. do?CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene, an oncolytic immunotherapy...
CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene, an oncolytic immunotherapy targeting bladder cancer. No product revenues to date; pursuing FDA BLA submission based on Phase 3 BOND-003 data.